Peer-reviewed veterinary case report
Tepoxalin raises VEGF but does not speed bone cancer growth in dogs
By Sottnik, J L et al.·Published in Veterinary and comparative oncology·2011·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft.
- Species:
- dog
Plain-English summary
A study looked at how the pain medication tepoxalin affects tumor growth in dogs with osteosarcoma, a type of bone cancer. While tepoxalin increased a protein called VEGF that can promote blood vessel growth in lab tests, it actually slowed down tumor growth in live dogs with this cancer. The researchers found that giving tepoxalin to dogs did not significantly raise VEGF levels in their bodies. This suggests that tepoxalin might help manage pain in dogs with tumors while also possibly slowing tumor growth.
People also search for: dog osteosarcoma treatment · tepoxalin for dog pain · does tepoxalin help with cancer in dogs
Abstract
The purpose of this study was to determine the impact of the non-steroidal anti-inflammatory drug tepoxalin on canine tumour cell growth and describe the changes associated with tepoxalin treatment. In vitro experiments were performed to assess tepoxalin-associated alterations in tumour cell growth. Clinically achievable tepoxalin concentrations did not significantly alter tumour cell growth in vitro. Vascular endothelial growth factor (VEGF) production and hypoxia-inducible factor-1α dose-dependently increased in vitro in the presence of tepoxalin. A canine osteosarcoma xenograft was used to determine in vivo effects of tepoxalin on tumour growth and angiogenesis. Despite increased VEGF in vitro, there was a significant growth delay associated with tepoxalin treatment. Normal dogs were administered tepoxalin to assess effects on systemic VEGF production, but not found to have significantly increased VEGF. These data suggest that tepoxalin may moderately inhibit tumour growth and may be administered as an analgesic to tumour-bearing dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21569197/